Pure Extracts Signs LOI For Joint Venture With Psyence Group

Pure Extracts (CSE: PULL) has entered into a letter of intent for a proposed joint venture with Psyence Group (CSE: PSYG). The proposed venture is to be focused on the extraction of psilocybin from mushrooms.

The venture partner, Psyence, is one of the first commercial psilocybin cultivation and extraction facilities operating under a federally legal framework. The company is based in South Africa, where it operates this facility and focuses on researching opportunities for the psychedelic substance, including palliative care, neuroscience, drug development and neurology. The firm also has select operations in Lesotho and Jamaica.

More specifically, the proposed venture is to develop “superior techniques” for the extraction of psilocybin from psychedelic mushrooms, as well as the development of advanced formulations. These advanced formulations are to be focused on the long-term treatment of psychological trauma and related mental health consequences, with the venture having the near-term goal of participating in a Canadian-based human clinical trial.

“This partnership with Pure Extracts will facilitate the importation of our standardized psychedelic mushrooms into Canada, giving us the opportunity to further optimize extraction methods and produce advanced products needed for safe clinical research. Our companies share the vision of providing the highest quality and most innovative psilocybin products for Canada, as evidenced by our facilities being constructed to GMP standards, and our commitment to rigorous scientific and clinical research for the development of transformational treatments for mental health disorders, with a particular focus on oncology palliative care.”

Dr Justin Grant, Chief Scientific Officer for Psyence

A timeline for the signing of a definitive agreement was not provided by either firm.

Pure Extracts last traded at $0.435 on the CSE.


FULL DISCLOSURE: Pure Extracts is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pure Extracts on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Tariffs Spark New Race for Critical Metals | Rob McEwen

Antimony Resources: The Bald Hill Project

They Laughed at $3,000 Gold, Now We’re Headed for $4,000! | Sean Roosen – Osisko Development Corp.

Recommended

Steadright Begins Preliminary Economic Assessment On TitanBeach Project

Three Miners Trapped Underground At Newmont’s Red Chris Mine

Related News

Pure Extracts Submits Application For First Natural Product Number

Pure Extracts (CSE: PULL) is one step closer to commercializing its functional mushroom operation. The...

Wednesday, February 3, 2021, 07:03:35 AM

Pure Extracts Receives Health Canada Processing License

Pure Extracts (CSE: PULL, listing pending) has seen Health Canada grant the firm its standard...

Thursday, October 1, 2020, 10:13:00 AM

Pure Extracts Scales Up THC, CBD Distillate Production

Pure Extracts (CSE: PULL) is looking to scale up its production of both THC and...

Tuesday, January 26, 2021, 07:01:18 AM

Pure Extracts Applies For Dealers License With Health Canada

Pure Extracts (CSE: PULL) continues to focus on the development of its mushroom-related operations in...

Thursday, March 4, 2021, 07:13:41 AM

Pure Extracts Outlines Psilocybin Study Timeline

Further details were released by Pure Extracts (CSE: PULL) this morning in relation to its...

Thursday, January 14, 2021, 07:24:18 AM